Combined Therapy of AXL and HDAC Inhibition Reverses Mesenchymal Transition in Diffuse Intrinsic Pontine Glioma. [electronic resource]
Producer: 20210914Description: 3319-3332 p. digitalISSN:- 1557-3265
- Animals
- Benzocycloheptenes -- pharmacology
- Biomarkers, Tumor
- Blood-Brain Barrier -- drug effects
- Cell Line, Tumor
- Combined Modality Therapy
- Diffuse Intrinsic Pontine Glioma -- drug therapy
- Disease Models, Animal
- Drug Synergism
- Epithelial-Mesenchymal Transition -- drug effects
- Histone Deacetylase Inhibitors -- pharmacology
- Histone Deacetylases -- metabolism
- Humans
- Immunohistochemistry
- Mice
- Protein Kinase Inhibitors -- pharmacology
- Proto-Oncogene Proteins -- antagonists & inhibitors
- Receptor Protein-Tyrosine Kinases -- antagonists & inhibitors
- Triazoles -- pharmacology
- Xenograft Model Antitumor Assays
- Axl Receptor Tyrosine Kinase
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.